Preliminary, Real-world, Multicenter Experience With Omadacycline for <i>Mycobacterium abscessus</i> Infections
Taylor Morrisette, Sara Alosaimy, Julie V. Philley, Carly Wadle, Catessa Howard, Andrew Webb, Michael P. Veve, Melissa Barger, Jeannette Bouchard, Tristan Gore, Abdalhamid M Lagnf, Iman Ansari, Carlos Mejía-Chew, Keira A. Cohen, Michael J. Rybak
Abstract
Abstract Twelve patients were treated with omadacycline (OMC) as part of a multidrug regimen for Mycobacterium abscessus. The majority of infections were of pulmonary origin (7/12; 58.3%). The median (interquartile range) duration of OMC was 6.2 (4.2–11.0) months. Clinical success occurred in 9/12 (75.0%) patients. Three patients experienced a possible adverse effect while on therapy.
Topics & Concepts
MedicineInterquartile rangeMycobacterium abscessusRegimenMycobacterium avium complexInternal medicineAdverse effectNontuberculous mycobacteriaMycobacteriumSurgeryTuberculosisPathologyMycobacterium research and diagnosisTuberculosis Research and EpidemiologyInfectious Diseases and Mycology